Targeted elimination of senescent cells by engineered extracellular vesicles attenuates atherosclerosis in ApoE<sup>-/-</sup> mice with minimal side effects.

Authors:
Zhang L; Wang C; Hu W; Bu T; Sun W and 7 more

Journal:
Theranostics

Publication Year: 2023

DOI:
10.7150/thno.87484

PMCID:
PMC10526664

PMID:
37771781

Journal Information

Full Title: Theranostics

Abbreviation: Theranostics

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Diagnostic Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing Interests: Y. L., Z. L., W. C., B. T., L. Z., S. W., L. J., W. L., and Z. B. have a patent pending for this technology. The authors have declared that no competing interest exists."

Evidence found in paper:

"This work was funded by the National Natural Science Foundation of China (82272010) and the Key R&D Project in Shaanxi Province (2023-ZDLSF-22) to L. Yuan and the R&D Program of Beijing Municipal Education Commission (KM202010025013) and BJNSF7222078 to H. Xing."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025